



Suicidal ideation, anxiety, and depression in 
patients with multiple sclerosis
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Multiple sclerosis (MS) is a chronic inflammatory and 
degenerative disease of the central nervous system that pre-
dominately affects women (women:men, 3:1) and individuals 
aged 20 to 40 years1. In this disease, autoimmune mechanisms 
cause an inflammatory cascade that eventually destroys the 
myelin, oligodendrocytes, and axons. Involvement of the 
white and gray matter produces clinical signs and symptoms 
that cause cumulative physical deficits, disability, and cogni-
tive and psychological alterations. The clinical manifestations 
of MS include fatigue, sensory and motor deficits, sphinc-
ter alterations, optic neuritis, diplopia, cerebellar signs, gait 
changes, spasticity, and cognitive dysfunction1. Given the 
wide range of symptoms and presentations, the patients’ 
quality of life, including their social and professional lives, are 
greatly affected. Currently, the etiology of MS is unknown, but 
genetic studies suggest that the disease results from complex 
interactions between genetic susceptibility and environmen-
tal factors1,2,3. 
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ABSTRACT
Psychiatric disorders frequently occur in patients with multiple sclerosis (MS); however, limited reports are available on these 
comorbidities. We aimed to investigate the relationships among MS, anxiety, depression, and suicidal ideation. Methods: One hundred and 
thirty two patients with relapsing-remitting MS were evaluated using the Expanded Disability Status Scale, Beck Depression Inventory-II 
(BDI-II), Beck Scale for Suicide Ideation (BSI), and Hospital Anxiety and Depression Scale. Results: A hierarchical regression analysis was 
performed to evaluate the variables. The regression equation significantly predicted the BSI score (R2 = 0.306; adjusted R2 = 0.273; F (9, 
125) = 9.18; p < 0.0005), and the BDI-II score was the only variable that contributed significantly to this model (p < 0.0005). Conclusions: 
A high prevalence of depression and anxiety, and a higher rate of suicidal ideation were identified in MS patients compared to the general 
population. The presence of depressive symptoms appeared to have a direct influence on the risk of suicide. 
Keywords: multiple sclerosis; suicidal ideation; anxiety; depression; risk factors; signs and symptoms.
RESUMO
Transtornos psiquiátricos frequentemente ocorrem em pacientes com esclerose múltipla (EM). No entanto, os artigos sobre estas comorbidades 
são limitados. Pretendemos investigar as relações entre EM, ansiedade, depressão e ideação suicida. Métodos: Cento e trinta e dois pacientes 
com EM remitente-recorrente foram avaliados usando a Escala de Estado de Incapacidade Expandida, Inventário de Depressão de Beck-II 
(IDB-II), Escala de Beck para Ideação de Suicídio (BSI) e Escala de Ansiedade e Depressão. Resultados: Uma análise de regressão hierárquica 
foi realizada para avaliar as variáveis. A equação de regressão previu significativamente o escore BSI (R2 = 0,306; R2 ajustado = 0,273; F (9, 125) 
= 9,18; p < 0,0005) e o escore no IDB-II foi a única variável que contribuiu significativamente para este modelo (p < 0,0005). Conclusões: Uma 
alta prevalência de depressão e ansiedade e uma maior taxa de ideação suicida foram identificadas em pacientes com EM em comparação 
com a população em geral. A presença de sintomas depressivos pareceu ter uma influência direta no risco de suicídio.
Palavras-chave: esclerose múltipla; ideação suicida; ansiedade; depressão; fatores de risco; sinais e sintomas.
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In addition to interfering with daily activities, the pain 
symptoms experienced by patients with MS have also been 
linked to severe depression4. Fatigue, another common 
symptom in patients with MS, may also be related to affec-
tive disorders, including depression. Thus, pain, fatigue, and 
depression may occur in conjunction with MS, and are often 
referred to as a set of symptoms in these patients1.
 Psychiatric disorders are frequently present in patients 
with MS, as higher incidences of mood disorders and anx-
iety have been found in these patients compared with 
age-matched healthy individuals4. Approximately 25% of 
patients with MS suffer from depression, compared with 
only 5% of the general population. In addition, depres-
sive symptoms can affect up to 50% of patients with MS, 
and depression can occur at any time during the course 
of the disease3. The mood disorders in these patients 
may be either a direct or indirect result of the medication 
used to treat MS or the so-called disease-modifying thera-
pies, as adverse psychological effects of various medica-
tions have been described2,3. Moreover, the mood disor-
ders may be the result of the psychological reactions and 
distress induced by the diagnosis and associated disabil-
ity1. Depression may also be secondary to the neuroana-
tomical and neurochemical changes related to disease-
induced neurodegeneration. Other factors contributing to 
the development of depression in MS patients include the 
loss of leisure opportunities, poor quality of relationships, 
high stress, and elevated levels of fatigue when compared 
to healthy individuals3.
The pivotal studies of interferon Beta 1b and interferon 
Beta 1a showed an increase in the risk of suicide and in 
the prevalence of depression when compared with the pla-
cebo group. Patients likely to develop depression are more 
susceptible5,6.
Although depression can exacerbate other MS symp-
toms, treatments for depression can improve patient adher-
ence rates to other disease-modifying therapies. However, 
despite the high prevalence of depressive symptoms in 
patients with MS, limited clinical research using appropri-
ate disease assessment scales exists. Therefore, the objective 
of the present study was to determine the prevalence and 
severity of depression, anxiety, and suicidal ideation among 
patients with MS and their relationship to functional status, 
disease severity, current treatment and antidepressant use.
METHODS
This study was approved by the Research and Ethics 
Committee of the Brasília (Brazil) Health Department (CAAE 
22477313.9.0000.5553) and written informed consent was 
obtained from all patients. For the inclusion of 132 recruited 
patients, between October 2015 and October 2016, 
200 patients diagnosed with the relapsing-remitting clinical 
form of MS (RRMS) according to the 2010 McDonald’s cri-
teria7 were evaluated from among a convenience sample 
of patients attending two specialized MS referral centers 
located in the Hospital District of Brasília and Hospital Santa 
Casa in São Paulo, Brazil. All patients were evaluated by two 
neurologists, one in each department, responsible for the 
care team of the MS patients. 
The inclusion criteria were a confirmed diagnosis of 
RRMS and an age between 18 and 60 years. The exclusion cri-
teria included patients in the relapse or acute phase of RRMS 
or the presence of pregnancy and infectious, neoplastic and 
psychiatric diseases, except for mood disorders, and patients 
in treatment with other psychiatric medications, such as 
antipsychotics and anxiolytics.
The attending physicians assessed the patient’s level of 
disability using the Expanded Disability Status Scale (EDSS)8, 
and two neuropsychologists and team of other doctors 
(trained examiners independent of the patient care team) 
employed the following three validated scales during their 
examination: the Beck Depression Inventory-II (BDI-II)9, 
Beck Scale for Suicide Ideation (BSI)10, and the Hospital 
Anxiety and Depression Scale (HADS; anxiety subscale: 
HADS-A; depression subscale: HADS-D)11,12.
The disease duration, marital status, and employment 
status of the patients were also recorded. Patients were clas-
sified in accordance with their MS severity, which was deter-
mined on the basis of their EDSS score as follows: severe 
(scores of 6.0–9.5), moderate (3.5–5.5), and mild (0.0–3.0). 
The degrees of depression and anxiety were based on the 
related scales’ cutoff points, as follows: no, or minimal, depres-
sion BDI-II score of 0–11, mild depression = 12–19, moderate 
= 20–35 and severe = 36–63; and this was similar for anxiety.10 
Absence of, or a depression score of 0, and a BDI-II indicating 
depression or anxiety, were scored as yes or no, and the score 
was used to stratify into two groups and simplify the statisti-
cal analysis; that is, patients who scored less than 18.5 points 
were considered as not being depressed and patients with a 
score greater than or equal to 18.5 points were considered as 
depressed13. In the HADS score, the abnormal scores range 
from 11–2111,12.
The data were analyzed using the PRISMTM v.6 software 
(www.graphpad.com/scientific-software/prism). Statistical 
analyses were performed using Spearman’s correlation coef-
ficient test and Fisher’s exact test. Differences were consid-
ered significant at p < 0.05.
Statistical analysis using Spearman’s correlation coeffi-
cient test identified significant positive correlations between 
the BDI-II scores and the following parameters: age, EDSS 
score, and antidepressant use.
A hierarchical regression analysis was performed to 
evaluate how well the variables of duration of illness, EDSS, 
HADS-A, BDI and HADS-D scores predicted the suicide ide-
ation as measured by the BSI scale. Age was entered as a sta-
tistical control variable.
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RESULTS
In total, 132 patients with RRMS were analyzed; of these, 
22% (29/132) were men and 78% (103/132) were women. The 
mean age of the patients was 35 years (range: 18-65 years). 
The occupational status among patients was 57.8% (48/132) 
being active in the workforce, while 42.2% (35/132) were not 
[Table 1]. The EDSS mean score for disease-related disabil-
ity was 2.5 (range: 0.0-7.5). Regarding the duration of the dis-
ease, 10.6% (14/132) of the patients were diagnosed with MS 
for < 1 year, 41.7% (55/132) for 1-5 years, 26.5% (35/132) for 
5-10 years and 21.3% (28/132) were diagnosed for > 10 years. 
(Table 1)
The current treatment of each patient at the time of 
the research was interferon (24.2% [32/132 patients]), glat-
iramer acetate (8.3% [11/132]), fingolimod (32.6% [43 / 132]), 
dimethyl fumarate (8.3% [11/132]), natalizumab (15.2% 
[20/132]), teriflunomide (4.5% [6/132]), alemtuzumab 0.8% 
[1/132]) and vitamin D (1.5% [2/132]). Overall, 4.5% (6/132) 
of the patients were not taking any medication for MS. 
Regarding the use of antidepressants, 34.8% (47/132) of the 
patients were taking antidepressants, while 65.1% (85/132) 
were not. 
According to the HADS scores, a mean of 7.6% of patients 
experienced anxiety, and 5.9%, depression. According to the 
BDI-II, 34% of the patients presented with depression The 
BSI scores of the patients revealed that 2.1% had suicidal ide-
ation. Among the patients in our sample, four patients had 
attempted suicide, and of these, two were taking interferon 
while the other were taking fingolimod (Tables 2 and 3).
The correlations were significant and positive, and ranged 
from low to moderate, associations among the variables. The 
BDI-II scores were correlated with age (r = 0.30, p = 0.008), 
EDSS score (r = 0.40, P = 0.0006), and antidepressant use 
(r = 0.27, p = 0.01) [Tables 1 and 2]. The HADS-A scores corre-
lated with the EDSS score (r = 0.26, p = 0.02) and age (r = 0.35, 
p = 0.02). The HADS-D scores correlated with antidepressant 
use (r = 0.33, P = 0.003). The BSI scores correlated with antide-
pressant use (r = 0.22, p = 0.05) and the EDSS scores (r = 0.27, 
p = 0.02). Lastly, the EDSS score correlated with the antide-
pressant use (r = 0.30, p = 0.01) (Table 4).
Table 1.  Demographic characteristics of the sample of the 



















Table 2.  Subgroups of RRMS patients by use of two different 




Depression No Depression p-value OR Lower Upper
Interferon use
Yes 6 26 0.03 0.361 0.136 0.956
No 39 61        
HADS-A classification
Yes 8 24 0.06 0.442 0.181 1.079
No 43 57        
HADS-D classification
Yes 5 27 0.37 0.62 0.214 1.793
No 23 77        
BSI classification
Yes 5 28 0.15 0.476 0.167 1.360
No 28 72        
Suicide attempt
Yes 2 30 1.00 0.767 0.154 3.810
No 8 92        
Fingolimod use 
Yes 16 27 0.59 1.226 0.573 2.624
No 29 60        
HADS-A classification
Yes 19 24 0.36 1.410 0.672 2.960
No 32 57        
HADS-D classification
Yes 13 30 0.07 2.138 0.909 5.028
No 15 74        
BSI classification
Yes 12 31 0.59 1.253 0.548 2.865
No 21 68        
Suicide attempt
Yes 4 39 0.72 1.419 0.379 5.317
No 6 83        
RRMS: relapsing remitting multiple sclerosis; DMTs: disease modifying 
therapies; BDI-II: Beck Depression Inventory-II; OR: odds ratio; CI: confidence 
interval; HADS-A: Hospital Anxiety and Depression Scale anxiety subscale; 
HADS-D: Hospital Anxiety and Depression Scale depression subscale; BSI: 
Beck Scale for Suicide Ideation.
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No significant association was found between the sub-
groups of patients treated with different disease modifying 
therapies and the presence of anxiety, depression and sui-
cidal ideation (Fisher’s exact test; Tables 2 and 3).
DISCUSSION
The aim of the present study was to investigate the rela-
tionships among MS, anxiety, depression, and suicidal ideation. 
Here, the patients’ mean age (35 years) and ratio of women to 
men were comparable to those reported previously, support-
ing that MS predominately affects women and young adults13,14. 
Interestingly, we found higher proportions of depression and 
anxiety symptoms and a higher rate of suicidal ideation in 
patients with MS when compared to the general population. In 
our sample, the presence of depressive symptoms, measured by 
the EDSS score, was found in 34% of the patients (n = 45), who 
had a higher median age (38 years), EDSS score (3.1) and dis-
ease duration (2.6 years) when compared with the patients with-
out depressive symptoms. As well, higher scores on this scale 
appeared to have a direct correlation with the risk of suicide in 
patients with MS, as shown by the correlation score (r = 0.27) 
and confirmed by the regression model designed. 
Similar to previous literature, our data showed a high 
prevalence of depressive symptoms in patients with MS14,15,16. 
Additionally, we identified a higher prevalence of depression in 
our patients with MS than that reported for the general popu-
lation16, with 30.6%, 29.3%, and 5.3% of our patients exhibiting 
mild, moderate, and severe depressive symptoms, respectively. 
Although   34% of our patients with MS had depression accord-
ing to the BDI-II scale, only 33.3% were on antidepressants, 
indicating that this comorbidity is often not suspected or iden-
tified during the clinical assessments of these patients and that 
few effective therapeutic measures against depression, includ-
ing both pharmacological and non-pharmacological strate-
gies, are employed in patients with MS. Consistent with the 
findings of other studies1,15,17,18, we found that age, EDSS score, 
disease duration, and occupational status were important fac-
tors associated with depression in patients with MS, based on 
the correlation of these parameters and the higher scores in 
the HADS and BDI-II scales. 





Yes No Lower Upper
BSI classification
Yes 5 28 0.058 3.357 0.906 12.435
No 5 94        
BDI-II
Yes 6 39 0.089 3.192 0.852 11.964
No 4 83        
HADS-A classification
Yes 6 45 0.184 2.567 0.687 9.584
No 4 77        
HADS-D classification 
Yes 5 23 0.035 4.304 1.150 16.113
No 5 99        
Antidepressant
Yes 4 43 0.744 1.225 0.328 4.578
No 6 79        
Interferon
Yes 2 30 1.00 0.767 0.154 3.810
No 8 92        
Fingolimod
Yes 4 39 0.728 1.419 0.379 5.317
No 6 83        
Disease duration (years)
< 1 0 14 0.724      
1–5 5 50        
5–10 2 33        
> 10 24 7        
DMTs: disease modifying therapies; BDI-II: Beck Depression Inventory-II; OR: odds ratio; CI: confidence interval; HADS-A: Hospital Anxiety and Depression Scale 
anxiety subscale; HADS-D: Hospital Anxiety and Depression Scale depression subscale; BSI: Beck Scale for Suicide Ideation.
Table 4. Multiple hierarchical regression - Age, MS duration, 
EDSS, and Anxiety and Depression Scales r2 of model: 0.273; 
p-value of model <0.0005.
Variable  Beta coefficient p-value
Age -0.046 0.185
Duration (months) 0.001 0.878
EDSS -0.017 0.928
HADS-A -0.183 0.057
BDI-II 0.219 < 0.0005
HADS-D 0.182 0.195
EDSS: Expanded Disability Status Scale; HADS-A: Hospital Anxiety and 
Depression Scale anxiety subscale; HADS-D: Hospital Anxiety and Depression 
Scale depression subscale; BDI-II: Beck Depression Inventory-II.
300 Arq Neuropsiquiatr 2018;76(5):296-301
The present study identified positive correlations, mod-
erately between the EDSS score and presence of depression, 
as measured with the BDI-II, and lower between the EDSS 
score and presence of suicidal ideation, as measured with 
the BSI. This relationship suggests simultaneity between dis-
ease progression and psychiatric disorders. Additionally, as 
reported previously, the relationship between the high rate 
of depression and suicidal ideation, through disease evo-
lution, side effects from MS, or the associated symptoms, 
is complex7. However, our study confirms the importance 
of these comorbidities in patients with MS and emphasizes 
the need for early diagnosis and treatment. The high level 
of suicidal ideation we identified in our patients with MS is 
noteworthy. Moreover, there was a lower significant correla-
tion between depression, as measured with the EDSS, and 
suicidal ideation, as measured with the BSI, in patients with 
MS. A study by de Cerqueira et al.1, involving 60 patients with 
MS, demonstrated that 16.6% of the participants had a past 
history of suicide attempt or current suicide risk and noted 
that comorbidity with depression was significantly higher in 
patients with a risk of suicide than it was in a control group. 
Therefore, despite the intensity of the correlation, it is clear 
that depression can affect the quality of life, and the relation-
ship of these parameters with the increased risk of death 
via suicide in individuals with MS, should alert clinicians 
to the issue. Hence, it is essential that researchers and clini-
cians effectively address this issue in both the laboratory and 
clinical practice.
When examining the link between MS medications and 
the presence of psychiatric disorders, we were unable to iden-
tify a relationship between patients who used immunomod-
ulatory or immunosuppressive treatments and the presence 
of depression, anxiety, and suicidal ideation. However, this 
conclusion is limited because over a third of the patients in our 
sample were taking antidepressants. On the other hand, stud-
ies such as the REGAIN study20 and EPOC study21 presented 
divergent conclusions regarding whether treatment with fin-
golimod, with or without antidepressants, causes or reduces 
depression in patients with MS. Other recent studies, such 
as the Consortium of MS Centers by Mirsky et al.22 in which 
they used a large database, affirm that there was no influence 
of interferon beta and use of antidepressants compared with 
other disease-modifying therapies, as in the present study.
This study has one major limitation. After being strati-
fied for analysis, the present study was limited in terms of the 
size of the analytical sample. Since this was a cross-sectional 
study with a convenience sample, the sample size was small 
and unidentified confounding factors may have affected the 
results. Studies with larger sample sizes and different designs 
need to be conducted to confirm our findings. 
Our findings support the use of systematic evaluations 
for psychiatric disorders in patients with MS, as the inci-
dences of depressive symptoms, anxiety symptoms, and sui-
cidal ideation are higher in these patients than they are in 
the general population. The presence of depressive symp-
toms in our sample suggests that depression has a direct 
influence on the risk of suicide in patients with MS, indi-
cating that such comorbidities need to be treated appropri-
ately to avoid negative outcomes.
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